Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications

Abstract

Ferucarbotran (Resovist) is the second clinically approved superparamagnetic iron oxide developed for contrast-enhanced MRI of the liver. The purpose of this review is to provide an overview on the properties, clinical development, and application of ferucarbotran. Safety data obtained during clinical phases I–III revealed a total of 162 adverse events… (More)
DOI: 10.1007/s00330-002-1721-7

Topics

7 Figures and Tables

Slides referencing similar topics